149 related articles for article (PubMed ID: 37651156)
1. DMF in CTCL: where do we go from here?
Allen PB
Blood; 2023 Aug; 142(9):753-754. PubMed ID: 37651156
[No Abstract] [Full Text] [Related]
2. Dimethyl fumarate restores apoptosis sensitivity and inhibits tumor growth and metastasis in CTCL by targeting NF-κB.
Nicolay JP; Müller-Decker K; Schroeder A; Brechmann M; Möbs M; Géraud C; Assaf C; Goerdt S; Krammer PH; Gülow K
Blood; 2016 Aug; 128(6):805-15. PubMed ID: 27268084
[TBL] [Abstract][Full Text] [Related]
3. Dimethyl fumarate treatment in relapsed and refractory cutaneous T-cell lymphoma: a multicenter phase 2 study.
Nicolay JP; Melchers S; Albrecht JD; Assaf C; Dippel E; Stadler R; Wehkamp U; Wobser M; Zhao J; Burghaus I; Schneider S; Gülow K; Goerdt S; Schürch CM; Utikal JS; Krammer PH
Blood; 2023 Aug; 142(9):794-805. PubMed ID: 37217183
[TBL] [Abstract][Full Text] [Related]
4. Romidepsin Plus Liposomal Doxorubicin Is Safe and Effective in Patients with Relapsed or Refractory T-Cell Lymphoma: Results of a Phase I Dose-Escalation Study.
Vu K; Wu CH; Yang CY; Zhan A; Cavallone E; Berry W; Heeter P; Pincus L; Wieduwilt MJ; William BM; Andreadis C; Kaplan LK; McCormick F; Porcu P; Brammer JE; Ai WZ
Clin Cancer Res; 2020 Mar; 26(5):1000-1008. PubMed ID: 31772119
[TBL] [Abstract][Full Text] [Related]
5. New drugs in cutaneous T-cell lymphomas.
Scarisbrick JJ
Curr Opin Oncol; 2016 Sep; 28(5):384-9. PubMed ID: 27390044
[TBL] [Abstract][Full Text] [Related]
6. DMF: a promising therapeutic option in CTCL.
Vancurova I
Blood; 2016 Aug; 128(6):745-6. PubMed ID: 27516426
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous T cell lymphoma: the helping hand of dendritic cells.
Edelson RL
Ann N Y Acad Sci; 2001 Sep; 941():1-11. PubMed ID: 11594563
[TBL] [Abstract][Full Text] [Related]
8. Future directions for pentostatin (Nipent) usage in dermatology.
Heald P
Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Targeting of MicroRNA-214 in Cutaneous T-Cell Lymphoma.
Kohnken R; McNeil B; Wen J; McConnell K; Grinshpun L; Keiter A; Chen L; William B; Porcu P; Mishra A
J Invest Dermatol; 2019 Sep; 139(9):1966-1974.e3. PubMed ID: 30876800
[TBL] [Abstract][Full Text] [Related]
10. Th2 cytokine mRNA expression in skin in cutaneous T-cell lymphoma.
Vowels BR; Lessin SR; Cassin M; Jaworsky C; Benoit B; Wolfe JT; Rook AH
J Invest Dermatol; 1994 Nov; 103(5):669-73. PubMed ID: 7963654
[TBL] [Abstract][Full Text] [Related]
11. Characteristics of cutaneous lymphomas in Osaka, Japan (1988-1999) based on the European Organization for Research and Treatment of Cancer classification.
Nagasawa T; Miwa H; Nakatsuka S; Itami S; Yoshikawa K; Aozasa K
Am J Dermatopathol; 2000 Dec; 22(6):510-4. PubMed ID: 11190442
[TBL] [Abstract][Full Text] [Related]
12. Antibiotics and Imiquimod for Cutaneous T-Cell Lymphoma in Veterans: A Patient Population with Agent Orange Exposure.
Del Guzzo CA; Kojadinovic A; Vinnakota RR; Geskin LJ; Newman JC; Langhoff E; Park YA; Bates SE; Dana AN
Oncologist; 2021 Sep; 26(9):727-e1488. PubMed ID: 33851477
[TBL] [Abstract][Full Text] [Related]
13. Control of polycythaemia vera with photochemotherapy in a patient with cutaneous T-cell lymphoma.
Cottrill C; Geller A; diSpaltro FX; Weissglass B; Klainer AS; Bisaccia E
Br J Haematol; 1994 Jan; 86(1):225-6. PubMed ID: 8011539
[TBL] [Abstract][Full Text] [Related]
14. Treatment of cutaneous T-cell lymphoma.
Zackheim HS
Semin Dermatol; 1994 Sep; 13(3):207-15. PubMed ID: 7986690
[TBL] [Abstract][Full Text] [Related]
15. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
16. The life cycle of cutaneous T cell lymphoma reveals opportunities for targeted drug therapy.
Berger CL; Edelson R
Curr Cancer Drug Targets; 2004 Nov; 4(7):609-19. PubMed ID: 15578918
[TBL] [Abstract][Full Text] [Related]
17. Cutaneous T-cell lymphoma and concomitant atopic dermatitis responding to dupilumab.
Mollanazar NK; Savage KT; Pousti BT; Jariwala N; Del Guzzo C; Haun P; Vittorio C; Rook AH; Kim EJ
Cutis; 2020 Sep; 106(3):131-132. PubMed ID: 33104116
[TBL] [Abstract][Full Text] [Related]
18. Analysis of clonality in cutaneous T cell lymphoma and associated diseases.
Wood GS
Ann N Y Acad Sci; 2001 Sep; 941():26-30. PubMed ID: 11594579
[TBL] [Abstract][Full Text] [Related]
19. Primary T Cells from Cutaneous T-cell Lymphoma Skin Explants Display an Exhausted Immune Checkpoint Profile.
Querfeld C; Leung S; Myskowski PL; Curran SA; Goldman DA; Heller G; Wu X; Kil SH; Sharma S; Finn KJ; Horwitz S; Moskowitz A; Mehrara B; Rosen ST; Halpern AC; Young JW
Cancer Immunol Res; 2018 Aug; 6(8):900-909. PubMed ID: 29895574
[TBL] [Abstract][Full Text] [Related]
20. Haematological cancer: Resiquimod—a topical CTCL therapy.
Killock D
Nat Rev Clin Oncol; 2015 Oct; 12(10):563. PubMed ID: 26305037
[No Abstract] [Full Text] [Related]
[Next] [New Search]
